Oncotarget

Reviews:

Who will benefit more from maintenance therapy of metastatic colorectal cancer?

Mingyi Zhou, Lingyu Fu and Jingdong Zhang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:12479-12486. https://doi.org/10.18632/oncotarget.23549

Metrics: PDF 661 views  |   HTML 1256 views  |   ?  


Abstract

Mingyi Zhou1, Lingyu Fu2 and Jingdong Zhang3

1Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang 110042, Liaoning Province, PR China

2Department of Clinical Epidemiology and Evidence Based Medicine, The First Hospital of China Medical University, Shenyang 110001, Liaoning Province, PR China

3Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang 110042, Liaoning Province, PR China

Correspondence to:

Jingdong Zhang, email: zhangjd0228@hotmail.com

Keywords: metastatic colorectal cancer; maintenance treatment; complete or partial response; stable disease; network meta-analysis

Received: July 04, 2017     Accepted: October 28, 2017     Published: December 21, 2017

ABSTRACT

Whether there is a difference in the efficacy of maintenance treatment for metastatic colorectal cancer (mCRC) between patients who achieve complete response (CR)/partial response (PR) and those with stable disease (SD) after induction treatment is controversial. PubMed, Cochrane Systematic Reviews, the Cochrane Collaboration Central Register of Controlled Clinical Trials, ClinicalTrials.gov, and databases of conferences were queried to identify randomized controlled trials evaluating the efficacy of maintenance treatment for mCRC patients. The search included articles dated from the inception of these resources until June 20, 2017. We estimated hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS). Network meta-analysis was performed to compare the efficacy of four regimens as maintenance treatment. Three randomized controlled trials comprising 1,301 patients were included in this network meta-analysis. Patients who achieved CR/PR after induction therapy benefited more from maintenance treatment than patients who achieved SD (PFS: HR [CR/PR] 1.50, 95% CI 1.09–2.08, vs. HR [SD] 1.35, 95% CI 1.04–1.74; OS: HR [CR/PR] 1.04, 95% CI 0.94–1.15, vs. HR [SD] 1.03, 95% CI 0.99–1.07). The results of network meta-analysis suggested that chemotherapy alone and observation were inferior to chemotherapy plus bevacizumab as maintenance treatment. Patients with mCRC who achieve CR/PR after induction therapy might benefit more from maintenance treatment than those with SD. Chemotherapy plus bevacizumab was the most appropriate regimen for maintenance treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 23549